Rapport Therapeutics, Inc. (NASDAQ:RAPP – Free Report) – Stock analysts at HC Wainwright raised their FY2026 earnings per share estimates for Rapport Therapeutics in a report released on Thursday, November 5th. HC Wainwright analyst D. Tsao now forecasts that the company will earn ($3.18) per share for the year, up from their previous estimate of ($4.51). HC Wainwright currently has a “Buy” rating and a $66.00 target price on the stock. The consensus estimate for Rapport Therapeutics’ current full-year earnings is ($3.34) per share. HC Wainwright also issued estimates for Rapport Therapeutics’ Q4 2026 earnings at ($0.72) EPS, Q1 2027 earnings at ($0.91) EPS, Q2 2027 earnings at ($1.06) EPS, Q3 2027 earnings at ($1.12) EPS, Q4 2027 earnings at ($1.19) EPS, FY2027 earnings at ($4.29) EPS, FY2028 earnings at ($5.37) EPS, FY2029 earnings at ($5.56) EPS and FY2030 earnings at ($4.58) EPS.
Rapport Therapeutics (NASDAQ:RAPP – Get Free Report) last announced its quarterly earnings results on Wednesday, November 4th. The company reported ($0.84) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.20) by $0.36.
A number of other equities research analysts have also recently issued reports on RAPP. BTIG Research raised their target price on Rapport Therapeutics from $75.00 to $89.00 and gave the company a “buy” rating in a research note on Tuesday, October 20th. Guggenheim reduced their price target on shares of Rapport Therapeutics from $70.00 to $66.00 and set a “buy” rating for the company in a report on Thursday, November 5th. TD Cowen restated a “buy” rating on shares of Rapport Therapeutics in a research report on Tuesday, October 20th. UBS Group lowered their price target on shares of Rapport Therapeutics from $71.00 to $64.00 and set a “buy” rating for the company in a research report on Thursday, November 5th. Finally, Wall Street Zen raised shares of Rapport Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday. One analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $64.50.
View Our Latest Stock Analysis on RAPP
Rapport Therapeutics Stock Performance
NASDAQ:RAPP opened at $25.96 on Monday. The business has a 50 day simple moving average of $33.25 and a 200 day simple moving average of $35.51. Rapport Therapeutics has a 12-month low of $22.06 and a 12-month high of $52.93.
Institutional Inflows and Outflows
A number of institutional investors have recently added to or reduced their stakes in the business. Algert Global LLC bought a new stake in shares of Rapport Therapeutics during the second quarter valued at about $9,327,000. Johnson & Johnson acquired a new stake in Rapport Therapeutics in the second quarter worth about $74,360,823. Legal & General Group Plc bought a new position in Rapport Therapeutics in the 2nd quarter valued at about $940,000. Bank of America Corp DE bought a new position in Rapport Therapeutics in the 2nd quarter valued at about $3,170,000. Finally, Walleye Capital LLC bought a new position in Rapport Therapeutics in the 2nd quarter valued at about $4,257,000.
Insider Buying and Selling at Rapport Therapeutics
In related news, CEO Abraham Ceesay sold 18,921 shares of the firm’s stock in a transaction that occurred on Tuesday, August 25th. The stock was sold at an average price of $49.57, for a total value of $937,913.97. Following the sale, the chief executive officer directly owned 467,187 shares in the company, valued at $23,158,459.59. This trade represents a 3.89% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Steven M. Paul bought 35,714 shares of the stock in a transaction that occurred on Thursday, October 22nd. The stock was acquired at an average price of $27.28 per share, for a total transaction of $974,277.92. Following the completion of the transaction, the director owned 77,380 shares in the company, valued at $2,110,926.40. This trade represents a 85.71% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. In the last 90 days, insiders acquired 1,031,174 shares of company stock valued at $22,023,898 and sold 46,477 shares valued at $1,958,709. Corporate insiders own 12.48% of the company’s stock.
Rapport Therapeutics Company Profile
Rapport Therapeutics is a Boston-based biotechnology company developing medicines for neurological and psychiatric disorders. Founded in 2022, the company focuses on small molecules designed to act on mechanisms that regulate the movement and function of proteins in the brain. Its research platform is intended to identify targets involved in neuronal signaling, including interactions that influence ion channels. Rapport’s pipeline includes RAP-219, an investigational medicine that modulates AMPA receptors and is being developed for focal epilepsy.
Read More
- Five stocks we like better than Rapport Therapeutics
- Why Kinder Morgan’s Chairman Just Bought $15 Million in Stock
- Rocket Lab’s Record Backlog Could Fuel a Rebound, But Neutron Raises the Stakes
- Don’t Let Their Low Yields Fool You: 3 Dividend Stocks Worth Watching
- A $4 Billion Jolt: NRG Energy Powers Data Center Ambitions
Receive News & Ratings for Rapport Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rapport Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
